Gsk (GSK) Net Equity Issued and Repurchased (2009 - 2026)

Gsk (GSK) has 18 years of Net Equity Issued and Repurchased data on file, last reported at $12.1 million in Q3 2026.

• For the quarter ending Q3 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $12.1 million; the trailing twelve-month figure through Sep 2026 stood at $56.6 million (changed N/A YoY), and the FY2025 full-year result was $20.0 million, down 21.96% from the prior year.
• Net Equity Issued and Repurchased was $12.1 million for Q3 2026 at Gsk, up from $10.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $24.4 million in Q4 2024 to a low of $9.7 million in Q1 2023.
• A 5-year average of $17.1 million and a median of $16.9 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased sank 57.37% in 2023 and soared 134.81% in 2024, its largest moves.
• Gsk's Net Equity Issued and Repurchased stood at $23.5 million in 2022, then slumped by 52.38% to $11.2 million in 2023, then surged by 118.31% to $24.4 million in 2024, then dropped by 23.64% to $18.6 million in 2025, then slumped by 35.11% to $12.1 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $12.1 million in Q3 2026, $10.8 million in Q1 2026, and $18.6 million in Q4 2025.